Subsequently, many specific PDE4 inhibitors have been found and are considered anti-inflammatory agents for asthma and COPD, as they can reduce oxidative stress, TNF-α production, and cytokine generation. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.